Physician profile
Daniel K Game
NPI 1457322059
$1,090.37
in general payments reported to CMS, 2019-2025
15 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $237 · 2020: $247 · 2021: $188 · 2022: $194 · 2023: $16.63 · 2024: $85.63 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $224.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $170.91 | 2019-2024 | Trelegy Ellipta |
| Mylan Specialty L.P. | $127.46 | 2019-2024 | |
| Philips North America LLC | $117.22 | 2020-2021 | |
| Harmony Biosciences LLC | $109.25 | 2022-2024 | |
| Inspire Medical Systems, INC. | $108.31 | 2025 | Inspire |
| Insmed, INC. | $99.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.41 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $78.04 | 2019-2024 | Uptravi, Opsumit |
| Astrazeneca Pharmaceuticals Lp | $75.72 | 2021-2023 | |
| Teva Pharmaceuticals USA, INC. | $46.72 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $19.55 | 2021 | |
| Eisai INC. | $15.28 | 2021 | |
| Verona Pharma, INC. | $14.04 | 2025 | Ohtuvayre |
| Advanced Respiratory, INC | $11.97 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.49 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Game listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.